Blueshift Asset Management LLC Invests $546,000 in Hologic, Inc. (NASDAQ:HOLX)

Blueshift Asset Management LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 7,573 shares of the medical equipment provider’s stock, valued at approximately $546,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of HOLX. Swedbank AB lifted its holdings in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after buying an additional 306,562 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Hologic by 22.2% in the third quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock worth $469,000 after buying an additional 1,048 shares in the last quarter. OneDigital Investment Advisors LLC lifted its holdings in shares of Hologic by 5.4% in the third quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider’s stock worth $576,000 after buying an additional 360 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of Hologic by 8.8% in the third quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider’s stock worth $294,000 after buying an additional 291 shares in the last quarter. Finally, Pathstone Holdings LLC raised its stake in Hologic by 7.7% in the third quarter. Pathstone Holdings LLC now owns 29,731 shares of the medical equipment provider’s stock valued at $2,422,000 after purchasing an additional 2,121 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Down 0.7 %

Shares of Hologic stock opened at $61.01 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The stock has a market capitalization of $13.69 billion, a price-to-earnings ratio of 19.25, a P/E/G ratio of 2.14 and a beta of 0.97. The company’s 50 day moving average price is $66.26 and its 200-day moving average price is $74.19.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of recent analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Evercore ISI lowered their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.